Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
Status:
Active, not recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
In this study the investigators will determine risk factors for liver fibrosis among HIV-HBV
co-infected patients in Lusaka, Zambia, and assess the long-term effectiveness of
antiretroviral drugs in the prevention and/or reduction of liver disease.
Details
Lead Sponsor:
University of Alabama at Birmingham University of North Carolina, Chapel Hill
Collaborators:
Fogarty International Center of the National Institute of Health John E. Fogarty International Center (FIC) National Institutes of Health (NIH)